Filing Summary
Registrant and period: The filing is an 8-K for Foresight Acquisition Corp., not P3 Health Partners Inc. It reports events beginning February 9, 2021, including the company’s IPO closing on February 12, 2021, and related disclosures signed February 16, 2021. Foresight was a newly formed special purpose acquisition company (SPAC) seeking an initial business combination.
Business Context and Transaction
- The SEC declared Foresight’s Form S-1 registration statement effective on February 9, 2021.
- The company completed an IPO of 31,625,000 units at $10.00 per unit, generating gross proceeds of $316.25 million. Each unit included one Class A common share and one-third of a redeemable warrant.
- Each whole public warrant is exercisable for one Class A share at $11.50 per share, subject to adjustment.
- Foresight also sold 832,500 private placement units to Foresight Sponsor Group, LLC and FA Co-Investment LLC at $10.00 per unit, generating gross proceeds of $8.325 million.
Financial Metrics, Liquidity, and Capital Structure
- The filing does not provide operating revenue, profit, cash flow, margins, or historical comparative financial statements.
- The filing does not disclose debt balances or conventional corporate liquidity metrics.
- $316.25 million of net IPO and private placement proceeds was placed in a trust account for public stockholders. The filing does not clearly reconcile this amount to the stated gross proceeds of $324.575 million.
- Trust funds generally may be released only upon completion of an initial business combination, certain approved amendments and related redemptions, or liquidation if no business combination is completed within 24 months after the IPO closing.
- The amended charter authorizes up to 200 million Class A shares, 20 million Class B shares, and 1 million preferred shares.
Material Changes and Other Events
- Foresight entered into its underwriting, warrant, trust, registration rights, sponsor subscription, indemnification, and business combination marketing agreements.
- Three directors—Brian Gamache, John Svoboda, and Robert Zimmerman—were appointed effective February 9, 2021.
- The company filed an amended and restated certificate of incorporation on February 9, 2021.
- Private placement warrants have transfer restrictions and, while held by the original purchasers or permitted transferees, may have cashless-exercise and other terms differing from public warrants.
Outlook, Risks, and Unusual Items
- No operating guidance or target business combination was identified in the provided filing text.
- The principal contingency is completion of an initial business combination within 24 months of the IPO closing; otherwise, public shares are generally subject to redemption, subject to applicable law.
- Trust funds are restricted and are not available for general operating purposes, except for permitted tax payments and limited dissolution expenses.
- The transaction creates dilution and potential future share issuance through sponsor securities, private placement units, and warrants.
Investor Verification Checklist
- Confirm the correct issuer: the filing identifies Foresight Acquisition Corp., while the request metadata identifies P3 Health Partners Inc.
- Verify the IPO closing date and the stated $316.25 million trust-account deposit against the final closing materials and bank or trustee disclosures.
- Review the warrant agreement for exercise, redemption, adjustment, and cashless-exercise provisions.
- Review the sponsor and private placement agreements for dilution, transfer restrictions, registration rights, and redemption terms.
- Confirm the deadline, redemption mechanics, and stockholder voting rights applicable to the future business combination.